Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw . 2021 Jul 28;19(7):839-868. doi: 10.6004/jnccn.2021.0032.
Manisha H Shah, Whitney S Goldner, Al B Benson, Emily Bergsland, Lawrence S Blaszkowsky, Pamela Brock, Jennifer Chan, Satya Das, Paxton V Dickson, Paul Fanta, Thomas Giordano, Thorvardur R Halfdanarson, Daniel Halperin, Jin He, Anthony Heaney, Martin J Heslin, Fouad Kandeel, Arash Kardan, Sajid A Khan, Boris W Kuvshinoff, Christopher Lieu, Kimberly Miller, Venu G Pillarisetty, Diane Reidy, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P Soares, Michael C Soulen, Jonathan R Strosberg, Craig R Sussman, Nikolaos A Trikalinos, Nataliya A Uboha, Namrata Vijayvergia, Terence Wong, Beth Lynn, Cindy Hochstetler
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
Read Full Article Here: https://doi.org/10.6004/jnccn.2021.0032